NorthWest Biotherapeutics Inc (NWBO)

[Margin Buu]

Optune is a device that looks like a skull cap which creates electrical fields to disrupt tumour cell division.

In 2018, the body which advises the NHS on treatments, NICE, said there was "insufficient evidence of its clinical effectiveness in terms of improvement in overall survival and progression-free survival to make the technology cost effective".

Basic reading comprehension would tell you that comment is in reference to Optune.

Again, March 12, 2022 - https://www.bbc.com/news/uk-england-hampshire-60690744

But health chiefs in the UK believe the treatment [Optune] is not cost-effective.

The National Institute for Health and Care Excellence makes decisions on treatments that are clinically and cost-effective for use on the NHS.

It said it recommended against the use of Optune "because there was insufficient evidence of its clinical effectiveness in terms of improvement in overall survival and progression-free survival to make the technology cost-effective".

Hopefully now that we have DCVax-L passing it’s Ph3 trial (see the JAMA article for more details) GBM patients will have access to better treatment and better OS odds.